ClinicalTrials.Veeva

Menu
S

Southern Star Research Institute LLC | San Antonio, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Risankizumab
Upadacitinib
Mirikizumab
ABT-494
Ustekinumab
Ontamalimab
Tulisokibart
Ozanimod
Vonoprazan
Lansoprazole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

28 of 63 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling
Crohn's Disease
Drug: Mirikizumab

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib
Recently updated

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical resp...

Active, not recruiting
Ulcerative Colitis
Drug: Placebo SC
Drug: Mirikizumab SC

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Active, not recruiting
Colitis, Ulcerative
Drug: Placebo
Drug: JNJ-77242113

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will ha...

Active, not recruiting
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Mirikizumab

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab togeth...

Enrolling
Crohn's Disease
Drug: Vedolizumab
Drug: Adalimumab

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate t...

Enrolling
Crohn's Disease
Drug: Placebo
Drug: TAK-279

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical...

Enrolling
Ulcerative Colitis
Drug: TAK-279
Drug: Placebo

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Enrolling
Ulcerative Colitis
Drug: Adalimumab
Drug: Lutikizumab Matching Placebo
Locations recently updated

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Enrolling
Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: placebo for risankizumab
Drug: risankizumab

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active ulcerative col...

Enrolling
Ulcerative Colitis
Drug: IV Placebo
Drug: SC Placebo
Locations recently updated

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's diseas...

Enrolling
Crohn's Disease
Other: SC Placebo
Drug: IV Tulisokibart

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative col...

Enrolling
Ulcerative Colitis
Drug: Mirikizumab

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This is an open-label study to evaluate the safety, efficacy, and PK of DNV3837 at a dose of 1.5 mg/kg actual body weight(BW)/day administered via IV...

Enrolling
Clostridium Difficile (C. Difficile)
Drug: DNV3837

This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of S...

Enrolling
Colitis Ulcerative
Drug: Placebo
Drug: SAR443122

ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with...

Enrolling
Ulcerative Colitis
Biological: ALTB-268

Trial sponsors

AbbVie logo
Lilly logo
Celgene logo
Shire logo
Merck Sharp & Dohme (MSD) logo
Boehringer Ingelheim logo
Janssen (J&J Innovative Medicine) logo
Phathom Pharmaceuticals logo
Takeda logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems